微生物組合作與授權協議（2016-2026）

微生物組交易的權威基準

微生物組領域的合作是由新的科學和創新的治療方法推動的，其合約結構反映了平台技術、生物製藥和數據驅動的藥物發現。

本報告對超過 250 項與微生物組相關的合作關係和許可協議進行了全面系統的分析，清楚地展示了夥伴關係在整個市場中的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對微生物組領域的合約實際是如何建構的提供了精確的理解。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清楚洞察基於平台類型、應用和合作夥伴概況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在不斷發展的治療領域（一個持續創新的領域），可視化合作夥伴的行為模式和反覆出現的合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解微生物組領域合作中價值、風險和控制權的分配至關重要。在那些仍在檢驗新的作用機轉和臨床療效的領域，其重要性更為突出。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 建構和評估新興技術交易
• 在清晰的市場環境下準備談判
• 評估平台合作夥伴關係和合作機會
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過250項與微生物組相關的合作和授權協議
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（按公司、平台和應用程式）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 微生物組領域交易中可靠的、依證的參考資料。
• 本報告結合了全面的合約資料涵蓋和詳細的合約層面分析，為在微生物組領域內建立、談判和評估夥伴關係關係提供了可靠的、依證證據的資源。

目錄

執行摘要

第1章：引言

第2章：微生物組的交易趨勢

• 過去幾年微生物組合作項目
• 微生物組交易中最活躍的參與者
• 微生物組契約：依合約類型分類
• 微生物組收縮：依治療領域分類
• 微生物組契約：依行業分類
• 微生物組契約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要微生物組契約

• 最暢銷的微生物組契約

第4章：最活躍的微生物組領域的締約方

• 微生物組領域最活躍的合約方
• 微生物組領域最活躍的簽約方的公司簡介

第5章 微生物組契約目錄

• 微生物組契約目錄

第6章 微生物組契約：依技術類型分類

• 合約目錄
• 合約目錄：依公司分類的微生物組契約（A-Z）
• 合約目錄：依合約類型分類的微生物組契約
• 合約目錄：依治療領域分類的微生物組契約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for microbiome dealmaking

Microbiome partnering is driven by emerging science and novel therapeutic approaches, with deal structures reflecting platform-based technologies, live biotherapeutics, and data-driven discovery.

This report provides a comprehensive and structured analysis of 250+ microbiome collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how microbiome deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by platform type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly innovative and still-evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within microbiome partnerships, particularly in areas involving novel mechanisms of action and emerging clinical validation.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark emerging technology transactions
• Prepare for negotiations with well-defined market context
• Evaluate platform partnerships and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 250+ microbiome collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, platform, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for microbiome dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how microbiome partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in microbiome dealmaking

• 2.1. Introduction
• 2.2. Microbiome deals over the years
• 2.3. Most active microbiome dealmakers
• 2.4. Microbiome deals by deal type
• 2.5. Microbiome deals by therapy area
• 2.6. Microbiome deals by industry sector
• 2.7. Deal terms for microbiome deals
  • 2.7.1 Microbiome deals headline values
  • 2.7.2 Microbiome deal upfront payments
  • 2.7.3 Microbiome deal milestone payments
  • 2.7.4 Microbiome royalty rates

Chapter 3 - Leading microbiome deals

• 3.1. Introduction
• 3.2. Top microbiome deals by value

Chapter 4 - Most active microbiome dealmakers

• 4.1. Introduction
• 4.2. Most active microbiome dealmakers
• 4.3. Most active microbiome deals company profiles

Chapter 5 - Microbiome contracts dealmaking directory

• 5.1. Introduction
• 5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

• Deal directory
• Deal directory - Microbiome deals by company A-Z
• Deal directory - Microbiome deals by deal type
• Deal directory - Microbiome deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Microbiome deals since 2016
• Figure 2: Active microbiome dealmaking activity since 2016
• Figure 3: Microbiome deals by deal type since 2016
• Figure 4: Microbiome deals by therapy area since 2016
• Figure 5: Microbiome deals by industry sector since 2016
• Figure 6: Microbiome deals with a headline value
• Figure 7: Microbiome deals with an upfront value
• Figure 8: Microbiome deals with a milestone value
• Figure 9: Microbiome deals with a royalty rate value
• Figure 10: Top microbiome deals by value since 2016
• Figure 11: Most active microbiome dealmakers since 2016
• Figure 12: Microbiome deals by technology type since 2016